Acute myeloid leukemia with paraneoplastic pemphigus successfully treated with a personalized antileukemic and immunosuppressive strategy.
Acute Myeloid Leukemia
Autologous stem cell transplantation
Bullous pemphigoid
Complete remission
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
23 May 2024
23 May 2024
Historique:
received:
13
03
2024
accepted:
13
05
2024
medline:
23
5
2024
pubmed:
23
5
2024
entrez:
23
5
2024
Statut:
aheadofprint
Résumé
Bullous pemphigoid (BP) is a rare blistering disease often considered a primary sign of a paraneoplastic syndrome. Retrospective studies have established its link with hematological malignancies, particularly lymphoproliferative disorders. Here, we present what we believe to be the inaugural case of successful simultaneous management of BP and de novo acute myeloid leukemia (AML) in a 28-year-old male patient. Given the rarity and severity of both conditions, our treatment strategy aimed to maximize efficacy by combining immunosuppressive therapy (initially plasmapheresis with high-dose corticosteroids, followed by anti-CD20 monoclonal antibody and intravenous immunoglobulins 2 g/m
Identifiants
pubmed: 38780802
doi: 10.1007/s00277-024-05804-x
pii: 10.1007/s00277-024-05804-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Genovese G et al (2019) New insights into the pathogenesis of Bullous Pemphigoid: 2019 update. Front Immunol 10:1506
doi: 10.3389/fimmu.2019.01506
pubmed: 31312206
pmcid: 6614376
Atzmony L et al (2017) Association of bullous pemphigoid with malignancy: a systematic review and meta-analysis. J Am Acad Dermatol 77:691–699
doi: 10.1016/j.jaad.2017.05.006
pubmed: 28645646
Schulze F et al (2015) Malignancies in pemphigus and pemphigoid diseases. J Invest Dermatol 135:1445–1447
doi: 10.1038/jid.2014.547
pubmed: 25560279
Ong E, Goldacre R, Hoang U, Sinclair R, Goldacre M (2014) Associations between bullous pemphigoid and primary malignant cancers: an English national record linkage study, 1999–2011. Arch Dermatol Res 306:75–80
doi: 10.1007/s00403-013-1399-5
pubmed: 23912480
Yang Y et al (2023) Associations between bullous pemphigoid and hematological diseases: literature review on mechanistic connections and possible treatments. Front Immunol 14:1155181
doi: 10.3389/fimmu.2023.1155181
pubmed: 36969223
pmcid: 10030799
Khoury JD et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic/Dendritic neoplasms. Leukemia 36:1703–1719
doi: 10.1038/s41375-022-01613-1
pubmed: 35732831
pmcid: 9252913
Arber DA et al (2022) International Consensus classification of myeloid neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140:1200–1228
doi: 10.1182/blood.2022015850
pubmed: 35767897
pmcid: 9479031
Döhner H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345–1377
doi: 10.1182/blood.2022016867
pubmed: 35797463
Di Lernia V, Casanova DM, Goldust M, Ricci C (2020) Pemphigus Vulgaris and Bullous Pemphigoid: update on diagnosis and treatment. Dermatol Pract Concept 10:e2020050
doi: 10.5826/dpc.1003a50
pubmed: 32642305
pmcid: 7319750
Parker JE et al (1997) Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 99:939–944
doi: 10.1046/j.1365-2141.1997.4763281.x
pubmed: 9432047
Frank DA, Mahajan S, Ritz J (1999) Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med 5:444–447
doi: 10.1038/7445
pubmed: 10202937
Schlenk RF et al (2013) The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood 122:1576–1582
doi: 10.1182/blood-2013-05-503847
pubmed: 23863898
Balestri R et al (2016) Malignancies in bullous pemphigoid: a controversial association. J Dermatol 43:125–133
doi: 10.1111/1346-8138.13079
pubmed: 26435381
Kim JH, Kim S-C (2019) Paraneoplastic Pemphigus: paraneoplastic autoimmune disease of the skin and Mucosa. Front Immunol 10:1259
doi: 10.3389/fimmu.2019.01259
pubmed: 31214197
pmcid: 6558011
Modiano P et al (1997) Bullous pemphigoid in association with cutaneous lesions specific to a myelodysplastic syndrome. Br J Dermatol 136:402–405
doi: 10.1046/j.1365-2133.1997.d01-1210.x
pubmed: 9115926
Lee YY, Bee PC, Lee CK, Naiker M, Ismail R (2011) Bullous pemphigoid in an elderly patient with myelodysplastic syndrome and refractory anemia coupled with excess of blast. Ann Dermatol 23:S390–S392
doi: 10.5021/ad.2011.23.S3.S390
pubmed: 22346286
pmcid: 3276805
Bauduer F, Barteau A, Truchet S, Massot-Bordenave J, Ducout L (1999) Bullous pemphigoid associated with the transformation of a preexisting myelodysplastic syndrome. Leuk Lymphoma 32:399–400
doi: 10.3109/10428199909167405
pubmed: 10037042